The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series

PURPOSE: To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. SUMMARY: Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:P T
Egile Nagusiak: Goriacko, Pavel, Yaghdjian, Vicken, Koleilat, Issam, Sinnett, Mark, Shukla, Harshal
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MediMedia USA, Inc. 2017
Gaiak:
Features
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642159/
https://ncbi.nlm.nih.gov/pubmed/29089726
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak